सभी अध्ययन
अधिकृतचरण I और चरण II (एकीकृत) - मनुष्यों को पहली बार प्रशासनहस्तक्षेपात्मक

A Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-DM1 in Subjects With Type 1 Myotonic Dystrophy Who are ≥18 to ≤65 Years

This research study, called ARO-DM1, is looking into a new medicine for people living with Type 1 Myotonic Dystrophy. We want to find out if this new medicine is safe for people to take and how well their bodies handle it. Researchers will also study how the medicine affects the disease. This first-stage study involves a small number of people and is focused on understanding side effects and proper dosing. Some participants will receive the new medicine, while others will receive a placebo – a harmless substance that looks like the medicine but has no active ingredients. Participants must be between 18 and 65 years old. This important step helps us learn if ARO-DM1 could be a helpful treatment in the future.

एक नजर में

स्थिति
अधिकृत
चरण
चरण I और चरण II (एकीकृत) - मनुष्यों को पहली बार प्रशासन
प्रायोजक
Sarepta Therapeutics Inc.
नामांकन लक्ष्य
58
प्रारंभ
29 जनवरी 2026

यह अध्ययन किस बारे में है?

This study is about a new medicine, ARO-DM1, for people who have Type 1 Myotonic Dystrophy. Myotonic Dystrophy Type 1 is a genetic condition that causes muscles to become weak and waste away over time. It can affect many parts of the body.

The main goal of this particular study is to check if ARO-DM1 is safe for people to take. Researchers will be carefully looking for any side effects and how strong these side effects might be. They also want to understand how the medicine moves through the body and how the body gets rid of it. This helps them work out the best dose and how often it should be given. We hope this research will bring us closer to new treatments for this condition.

This is an early-stage study, meaning it's one of the first times this medicine is being tested in humans. It's an important step for new medicines to go through these stages to make sure they are safe and potentially effective before they can be used more widely.

मुख्य निष्कर्ष

  • This study is testing a new medicine (ARO-DM1) for Type 1 Myotonic Dystrophy.
  • मुख्य लक्ष्य दवा की सुरक्षा की जांच करना और शरीर इसे कैसे संभालता है, यह देखना है।.
  • Participants will receive either the new medicine or a dummy medicine (placebo).
  • It's an early-stage study, focused on understanding side effects and dosing.
  • You must be an adult, aged 18 to 65, to be considered for participation.

कौन पात्र हो सकता है?

This study is designed for adults. To take part, you need to be aged 18 years or older. There is no upper age limit listed, which means people older than 65 might also be considered, but the current range specified is up to 65 years.

क्या यह अध्ययन आपके लिए उपयुक्त हो सकता है?

यह देखने के लिए इन त्वरित प्रश्नों का उत्तर दें कि क्या आप पात्र हो सकते हैं। यह केवल एक मार्गदर्शिका है — अंतिम निर्णय शोध टीम द्वारा लिया जाता है।.

  1. क्या आप 18 वर्ष या उससे अधिक आयु के हैं?
  2. Are you 65 years old or younger?
  3. Have you been diagnosed with Type 1 Myotonic Dystrophy?
  4. क्या आप नियमित नियुक्तियों में शामिल हो सकते हैं और अध्ययन निर्देशों का पालन कर सकते हैं?
अपने परिणाम देखने के लिए हर प्रश्न का उत्तर दें।.

भागीदारी में क्या शामिल है?

If you decide to take part in this study, you will likely have several visits to a clinic or hospital. These visits will involve various checks, such as blood tests, physical examinations, and possibly tests to see how your muscles are working. You will receive either the study medicine, ARO-DM1, or a placebo (a dummy medicine) as an injection. Neither you nor the study team will know which you are receiving. The study involves regular follow-up appointments to monitor your health, any side effects, and how your body is responding to the treatment. The total length of your participation, including the treatment period and follow-up, will be decided by the study doctors.

संभावित जोखिम और लाभ

Taking part in a study like this might offer a chance to try a new treatment that isn't available yet, which could potentially help your condition. However, there are also risks, as the medicine is still being tested and could cause unexpected side effects. Some side effects might be uncomfortable or even serious. You will be closely monitored by doctors and nurses throughout the study. Remember, joining is always your choice, and you can withdraw from the study at any time, for any reason, without it affecting your usual medical care.

स्थान (4)

कुछ साइट स्थान अनुमानित हैं। हम इसे सुधार रहे हैं — कृपया यात्रा करने से पहले परीक्षण टीम से सत्यापित करें।.
  • —
    असत्यापित
    स्पेन
  • —
    असत्यापित
    जर्मनी
  • —
    असत्यापित
    बेल्जियम
  • —
    असत्यापित
    इटली

सामान्य प्रश्न

What is Type 1 Myotonic Dystrophy?

It's a genetic condition that causes muscles to weaken and waste away over time, affecting movement and other body functions.

'प्लेसबो' क्या है?

A placebo is a substance that looks exactly like the study medicine but doesn't contain any active ingredients. It helps researchers compare the effects of the new medicine.

What does 'dose-escalating' mean?

It means that different participants will receive different doses of the medicine, starting with small amounts and gradually increasing, so researchers can find the safest and most effective dose.

Why is this an 'early-stage' study?

This is one of the first times the medicine is being tested in people. It's focused on checking safety and how the body handles the medicine before it moves to larger studies.

क्या मुझे पता चलेगा कि मुझे असली दवा मिल रही है या प्लेसीबो?

No, during the study, neither you nor the study team will know whether you are receiving the active medicine or the placebo. This is to ensure fair results.

और अधिक जानने के लिए कैसे पता करें

किसी अध्ययन में भाग लेने का निर्णय लेने से पहले हमेशा अपने जीपी या विशेषज्ञ से बात करें।.

चर्चा

समुदाय चर्चा

हमारे फोरम द्वारा संचालित community.patient.info. कृपया सम्मानजनक रहें — यह चिकित्सा सलाह नहीं है।.